Eiger BioPharmaceuticals' Series A - II Round

Eiger BioPharmaceuticals raised a round of funding on November 20, 2014.

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger's pipeline includes preclinical NCEs fr…

Articles about Eiger BioPharmaceuticals' Series A - II Round: